Company: AGIO
Filing Date: 2025-07-31
Form Type: 10-Q
Source: 0001439222-25-000089
Chunk: 114

Company: AGIOS PHARMACEUTICALS, INC.
Filing Date: 2025-07-31
Form: 10-Q
Item: Part I, Item 1
Chunk 114
---
$(199,136)$(178,271)

See accompanying Notes to Condensed Consolidated Financial Statements.

3

AGIOS PHARMACEUTICALS, INC.

Condensed Consolidated Statements of Stockholders' Equity

(Unaudited)Common StockAdditionalPaid-InCapitalAccumulatedOtherComprehensive Income(Loss)AccumulatedDeficitTreasury StockTotalStockholders’Equity(in thousands, except share amounts)SharesAmountSharesAmountBalance at December 31, 202473,372,696 $73 $2,493,811 $(1,518)$(148,924)(16,216,411)$(802,486)$1,540,956 Unrealized gain on available-for-sale securities— — — 1,883 — — — 1,883 Common stock issued under stock incentive plan and ESPP730,496 1 1,618 — — — — 1,619 Stock-based compensation expense— — 11,359 — — — — 11,359 Net loss— — — — (89,289)— — (89,289)Balance at March 31, 202574,103,192 $74 $2,506,788 $365 $(238,213)(16,216,411)$(802,486)$1,466,528 Unrealized gain on available-for-sale securities— — — 290 — — — 290 Common stock issued under stock incentive plan and ESPP151,764 — 65 — — — — 65 Stock-based compensation expense— — 14,692 — — — — 14,692 Net loss— — — — (112,020)— — (112,020)Balance at June 30, 202574,254,956 $74 $2,521,545 $655 $(350,233)(16,216,411)$(802,486)$1,369,555 

Common StockAdditionalPaid-InCapitalAccumulatedOtherComprehensiveLossAccumulatedDeficitTreasury StockTotalStockholders’Equity(in thousands, except share amounts)SharesAmountSharesAmountBalance at December 31, 202372,161,489 $72 $2,436,523 $(441